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Abstract
Objective—Significant deficiencies exist in the communication of prognosis for patients
requiring prolonged mechanical ventilation after acute illness, in part because of clinician
uncertainty about long-term outcomes. We sought to refine a mortality prediction model for
patients requiring prolonged ventilation using a multicentered study design.
Design—Cohort study.
Setting—Five geographically diverse tertiary care medical centers in the United States
(California, Colorado, North Carolina, Pennsylvania, Washington).
Patients—Two hundred sixty adult patients who received at least 21 days of mechanical
ventilation after acute illness.
Interventions—None.
Measurements and Main Results—For the probability model, we included age, platelet
count, and requirement for vasopressors and/or hemodialysis, each measured on day 21 of
mechanical ventilation, in a logistic regression model with 1-yr mortality as the outcome variable.
We subsequently modified a simplified prognostic scoring rule (ProVent score) by categorizing
the risk variables (age 18–49, 50–64, and >65 yrs; platelet count 0–150 and >150; vasopressors;
hemodialysis) in another logistic regression model and assigning points to variables according to β
coefficient values. Overall mortality at 1 yr was 48%. The area under the curve of the receiver
operator characteristic curve for the primary ProVent probability model was 0.79 (95% confidence
interval, 0.75–0.81), and the p value for the Hosmer-Lemeshow goodness-of-fit statistic was .89.
The area under the curve for the categorical model was 0.77, and the p value for the goodness-of-
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fit statistic was .34. The area under the curve for the ProVent score was 0.76, and the p value for
the Hosmer-Lemeshow goodness-of-fit statistic was .60. For the 50 patients with a ProVent score
>2, only one patient was able to be discharged directly home, and 1-yr mortality was 86%.
Conclusion—The ProVent probability model is a simple and reproducible model that can
accurately identify patients requiring prolonged mechanical ventilation who are at high risk of 1-yr
mortality.
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Many patients who survive the first few days of critical illness do so with multiple persistent
organ failures, ultimately becoming dependent on mechanical ventilation for prolonged
periods (1). Up to 10% of patients who develop acute respiratory failure require prolonged
mechanical ventilation (PMV) (2). The number of patients receiving PMV has increased in
recent years, likely as a result of improvements in acute management and supportive care for
critically ill patients (2, 3). As the population ages, it is expected that this number will
increase further, because advanced age is a key risk factor for PMV (3, 4). One-yr mortality
for patients receiving PMV is high (5–9), and only 11% percent of patients are functionally
independent and living at home by 1 yr (9, 10). During the year of their illness, 74% of the
patients’ days alive are spent in a hospital, postacute care facility, or receiving home health
care.
Recent empirical studies have documented serious shortcomings in the process of
decisionmaking about life support for patients on PMV. Up to 93% of families and surrogate
decisionmakers do not receive any information about expected long-term survival despite
explicit wishes to have this information (11, 12). In one study, 93% of surrogate
decisionmakers had high expectations for survival of patients on PMV compared with only
44% of physicians for the same patients (12). These deficiencies are problematic for two
reasons. First, they are a threat to patient-centered care because existing data suggest that
patients often prefer treatment focused on palliation in the setting of a poor prognosis (13–
15). Second, patients receiving PMV are among the highest consumers of healthcare
resources (16) and, from a societal perspective, it is important to ensure that the provision of
this very expensive resource is reserved for patients who would choose such treatments after
a careful discussion of the risks and benefits.
Although there are likely several reasons for suboptimal discussions about prognosis
between physicians and families, one important reason is clinicians’ uncertainty about the
long-term outcomes of patients on PMV (17–20). This is perhaps not surprising because
most intensive care unit (ICU) clinicians have little opportunity to follow patients after they
leave the ICU and therefore little opportunity to refine their prognostic abilities regarding
long-term outcomes. To address this gap for patients on PMV, the ProVent model was
developed and internally validated at a single tertiary care medical center to predict 1-yr
mortality for patients receiving at least 21 days of mechanical ventilation after acute illness
(5). Using four easily identified clinical variables (age, platelet count, on-going use of
vasopressors, and hemodialysis), the ProVent model had very good discrimination (area
under the curve [AUC] of the receiver operator characteristic curve 0.81) and calibration for
identifying patients who were at high risk of death after PMV. To establish broader
applicability, we sought to refine the ProVent model and provide external validity using data
from a heterogeneous group of patients from multiple hospitals across the United States.
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In a retrospective cohort design, patients were enrolled from five tertiary care centers
including the University of Washington, University of California at San Francisco, Denver
Health Medical Center, the Hospital of the University of Pennsylvania, and Duke University
Medical Center. Centers were selected based on geographic distribution and access to a
broad range of medical, surgical, and trauma patients requiring PMV. None of the centers
had contributed data to the original development model. The research protocol was approved
by institutional review boards at each of the five centers as well as the coordinating center at
the University of North Carolina.
Patients receiving mechanical ventilation in 2005 for at least 14 days after acute illness,
uninterrupted by >48 hrs of unassisted breathing, were followed, and patients who were still
receiving mechanical ventilation by day 21 were included in the study. Exclusion criteria
included age <18 yrs old; diagnosis of acute or chronic neuromuscular disease such as
Guillain-Barré syndrome, muscular dystrophy, or myasthenia gravis; patients sustaining
extensive burn injuries; and requirement for chronic mechanical ventilation before acute
admission. These inclusion and exclusion criteria are the same criteria used for the original
model development. Patients were identified by screening records of mechanical ventilation
for all patients admitted to adult medical, neurologic, surgical, cardiac, or trauma ICUs.
Either consecutive samples or random samples of patients were enrolled at each center
depending on the number of patients who were eligible.
Data were abstracted from medical records by two trained individuals at each site. One
abstractor who was blinded to patient outcome determined eligibility and collected data on
demographic variables and risk factors. The other abstractor collected data on hospital
outcomes. The principal investigator at each site reviewed the first ten charts that were
abstracted and a random sample of ten subsequent charts to confirm accuracy of data and
identify errors that would prompt review of additional charts and correction.
Descriptive variables included age, admission source, primary ICU service, ICU admission
diagnoses, and comorbidities based on a modified Charlson score (21). Race and ethnicity as
listed in medical records were abstracted to provide information regarding generalizability.
We assessed severity of illness on ICU admission using the Acute Physiology and Chronic
Health Evaluation III score (22) determined using the worst values measured within the first
24 hrs of index ICU admission. Because the objective of this study was to provide external
validity for the mortality prediction model developed at a single center, we only included the
four original predictive variables in the probability model. The four predictor variables
collected on day 21 of mechanical ventilation included age, platelet count, and requirement
for vasopressors and/or hemodialysis.
Requirement for hemodialysis was defined as provision of any form of renal replacement
therapy on or within 48 hrs of day 21 of mechanical ventilation. The primary outcome
variable was 1-yr mortality using death dates obtained by linking patient records to the
National Death Index or the Washington State Death Database. We also assessed several in-
hospital outcome variables, including duration of mechanical ventilation, liberation from
mechanical ventilation in the hospital defined as unassisted breathing for 7 consecutive days,
ICU and hospital length of stay, and hospital mortality. For patients who died during the
index hospitalization, records were reviewed for use of mechanical ventilation, vasopressors,
and hemodialysis within 72 hrs of death as well as mechanical ventilation, vasopressors, or
cardiopulmonary resuscitation on the day of death.
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Descriptive statistics are presented using mean ± SD for normally distributed continuous
variables, median with interquartile range for nonnormally distributed continuous variables,
and proportions for categorical variables. To validate the predictive capabilities of the four
ProVent predictor variables, we included all variables in a logistic regression model
(ProVent probability model) with 1-yr mortality as the outcome variable. We assessed
model discrimination using the AUC and model calibration using the Hosmer-Lemeshow
goodness-of-fit statistic comparing observed mortality with predicted mortality for each
decile of predicted risk. Because a second external cohort was not available, a bootstrap
method was used to validate the model by repeating 1000 random samples consisting of
60% of the cohort to provide a 95% confidence interval for the AUC.
After validation of the primary ProVent probability model that used the risk variables as
they were measured, we categorized the risk variables and included them in a second logistic
regression model. Before initiation of data collection, the investigators elected to modify the
cut point for age from the original ProVent score (5). Specifically, two cut points were
included for age (age 50 and 65 yrs) rather than one at age 50 yrs to better reflect the higher
risk associated with advancing age. Other categorical variables remained the same. We then
created a new ProVent score by assigning points to each risk factor according to the β
coefficients in the logistic regression model. Long-term survival based on the range of
cumulative scores was represented by Kaplan-Meier curves, and the performance of the
ProVent score was assessed in a third logistic regression model.
Data were analyzed using SAS software (SAS Institute Inc., Cary, NC). Kaplan-Meier
curves were drawn using Stata 8.0 software (Stata, College Station, TX).
RESULTS
A total of 289 patients were enrolled from the five centers. Of those, 260 patients (90%) had
complete data for risk variables and were included in analyses. Patient characteristics and
outcomes are shown in Table 1. The mean age ± SD of patients was 55 ± 17 yrs, and 41%
were female. Patients were diverse in diagnosis, admission source, and primary critical care
service including medical, surgical, trauma, and neurologic units. Median (interquartile
range) duration of mechanical ventilation was 30 (25–40) days, and median ICU and
hospital lengths of stay were 34 (28 – 48) and 44 (33–70) days, respectively. Twenty-eight
percent of patients died in the hospital and 12% were discharged home. Of the patients who
died in the hospital, 90% were receiving mechanical ventilation and 46% were receiving
vasopressors within 72 hrs of death. Only 8% of patients received cardiopulmonary
resuscitation at the time of death. Patients who died in the hospital received a median of 32
(26 – 43) days of mechanical ventilation before death. One-yr mortality for the cohort was
48%. The 29 patients not included in analyses as a result of incomplete data for risk
variables were similar in mean age (57 ± 15 yrs), gender (39% female), comorbidity score
(median, 1 [0 –3]), and 1-yr mortality (48%).
In the ProVent probability logistic regression model (see subsequent equation), each of the
four ProVent variables was independently associated with 1-yr mortality, including age
(odds ratio [OR], 1.04; 95% confidence interval [CI], 1.03– 1.06) for each additional year of
age, platelet count (0.996; 0.994–0.998) for each increase of 1 × 109/L, vasopressors (2.96;
1.03–8.46) relative to no vasopressors, and hemodialysis (2.52; 1.00–6.34) relative to no
hemodialysis. Enrollment center was not an independent predictor when included as a model
variable. Discrimination as measured by the AUC was 0.79 (95% CI, 0.75–0.81). In
comparison, the AUC for the Acute Physiology and Chronic Health Evaluation III score
measured at ICU admission and 1-yr mortality was 0.63. A comparison of observed vs.
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predicted mortality for the model is shown in Table 2. The Hosmer-Lemeshow goodness-of-
fit statistic was 3.58 with 8 df (p = .89).
Using the ProVent probability model, the predicted probability of death within 1 yr can be
calculated using the following equation:
where A = person’s age (in years); P = platelet count (in 109/L units), V = 1 if on
vasopressors or = 0 if not, and H = 1 if on hemodialysis or = 0 if not; “exp” is the
exponential constant (2.71828). Variables are measured on day 21 of mechanical ventilation.
Requirement for hemodialysis is defined as provision of hemodialysis on or within 48 hrs of
day 21 of mechanical ventilation.
The second logistic regression model with categorized variables had an AUC of 0.77, and
the Hosmer-Lemeshow goodness-of-fit statistic was 5.70 with 5 df (p = .34). Point values
were assigned according to the β values from the second model as shown in Table 3 to
generate the ProVent score. Two points were assigned to age ≥65 yrs, and 1 point was
assigned to each of the other risk factors including age 50–64 yrs, platelet count ≤150 × 109/
L, and requirement for vasopressors or hemodialysis on day 21 of mechanical ventilation.
Scores could range from 0 to 5 points. The third logistic regression model using the
cumulative ProVent score had an AUC of 0.76, and the Hosmer-Lemeshow goodness-of-fit
statistic was 1.86 with 3 df (p = .60). Table 4 and Figure 1 show 1-yr mortality and long-
term survival for patients according to their ProVent score. For patients in the highest risk
groups (ProVent score >2 points), hospital mortality was 43%, yet only one patient was
discharged home, and 1-yr mortality was 86%.
DISCUSSION
In a multicenter cohort study, the primary ProVent probability model accurately predicted
risk of 1-yr mortality for patients requiring at least 21 days of mechanical ventilation. The
cohort included a racially diverse group of patients from medical, surgical, and neurologic
ICUs. The model has good discrimination and excellent calibration for patients at all levels
of risk. The ProVent model uses only four variables that are easily measured on day 21 of
mechanical ventilation. The model does not require subjective assessments such as the
Glasgow Coma Scale that can be affected by sedation practices or primary admission
diagnosis, which can be uncertain in patients presenting with multiorgan failure (23).
Predicted mortality for patients can be obtained by using the prediction equation provided.
Alternatively, the model has been converted to a simple scoring rule (ProVent score) to aid
in clinical application at the bedside if a computer or hand-held device is not available to
complete the probability equation. Less than 15% of patients with ProVent scores >2 were
alive after 1 yr. The Model for End-Stage Liver Disease score, which uses three objective
variables to predict survival in patients with advanced liver disease, provides a clear
example of how simple prediction rules can gain wide general use in the acute care setting
for purposes of risk prediction and scarce resource allocation (24, 25).
Prognostication is not straightforward in many clinical conditions. PMV presents unique
challenges for long-term prognostication because few inpatient clinicians participating in
ICU decisionmaking have experience with patient outcomes beyond hospital discharge.
Existing severity of illness measures using variables measured on the day of ICU admission
do not perform well in the PMV population as demonstrated in previous analyses (26) and in
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the current assessment of the Acute Physiology and Chronic Health Evaluation III system in
this cohort. Therefore, a model specific to the PMV population is necessary. Published
outcome studies provide mean outcomes for large cohorts (5–9) but are not sufficiently
tailored to individual patient characteristics to reliably inform clinical prognostication.
This validated prediction model for long-term outcome can: 1) standardize illness severity in
observational and interventional studies of chronically critically ill patients; 2) help
determine appropriate levels of postacute care (27–29); and 3) increase clinicians’
confidence in responding to informational needs of patients, families, and surrogate
decision-makers (30, 31). It is yet to be determined whether the ProVent models are more
accurate than physician estimates of high risk, and like with any prognostic model, the
ProVent models are intended to complement the a priori assessments of an experienced
clinician rather than replacing clinical judgment (32). Given the inherent limitations in
translating data on population-level outcomes to individual risk estimates, the use of scoring
systems as a sole guide to making decisions about whether to initiate or continue to provide
intensive care is inappropriate by current ethical standards (33). However, the data derived
from these systems can provide relevant information for decisionmaking, especially when
combined with physician estimates of outcome.
Another consideration is whether clinicians will use prognostic information from the
ProVent model. The Study to Understand Prognoses and Preferences for Outcomes and
Risks of Treatment (34) was a large randomized controlled trial in which physicians were
given prognostic estimates for individual patients based on a sophisticated prognostic model.
The intervention had no significant impact on the main outcomes, in part because only 20%
of physicians disclosed the prognostic information to surrogates. These data suggest that to
meaningfully impact care, the ProVent score may need to be part of a more sophisticated
decision support process that is acceptable to clinicians. Examples of decision support
interventions that could incorporate ProVent data and may benefit patients on PMV include
structured family meetings led by intensivists or palliative care-trained clinicians (35–38) or
formal decision support tools that can be shared with patient surrogates in a formal setting
(39). Future iterations of the ProVent model should involve measurement of variables before
21 days of mechanical ventilation to aid decisionmaking earlier in the course of ICU care.
Multiple studies have suggested that intensivist perceptions of extremely poor prognosis are
associated with less aggressive or invasive care (40–42). Prognoses in the intermediate range
may be less likely to impact decisionmaking, but intermediate prognoses are still valuable in
the setting of prolonged ventilation and chronic critical illness. For example, patients with a
ProVent score of 3 have predicted 1-yr mortality of 81% (95% CI, 67–94). Although
clinicians and families will not perceive this as hopeless, it is likely to help focus their
attention on the patient’s desires for prolonged invasive care in the context of lower
expectations for survival, a universally high symptom burden (43), and poor expected
functional outcomes in long-term survivors (6 – 8).
Our study has several limitations. Although we refined our model in a geographically
diverse population, we conducted our study primarily in large tertiary centers. However,
previous literature indicates that large centers take care of the majority of patients requiring
PMV as a result of the greater complexity of their patient populations and transfer practices
from smaller community hospitals (44). The confidence interval around the AUC and
measures of calibration for the primary probability model using the original continuous
variables are excellent. However, further validation of the modified scoring rule (ProVent
score) in a larger external sample is indicated. The retrospective study design could have
introduced bias in ascertainment of data, but patient eligibility and risk variables were easily
identified in medical records, and investigators measuring risk variables were blinded to
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patient outcomes. Our study also did not assess long-term functional status, an important
factor in decisionmaking for many patients (41), because the study design did not allow for
measurement of those outcomes. Because some patients or surrogates opted not to pursue
full life support throughout their entire course, the model likely predicts an interplay of
physiological and social factors rather than the bare natural history of disease (15, 45). This
is true of all mortality models derived from clinical populations.
CONCLUSION
The ProVent probability model is a simple and reproducible model that can accurately
identify patients requiring PMV who are at high risk of 1-yr mortality. When paired with
clinical judgment, this model may increase clinicians’ ability to discuss the likely outcomes
of treatment and to tailor care to achieve patient-centered goals. Future studies should
examine similar models using variables measured earlier in the course of prolonged
ventilation and outcomes that include long-term functional status.
Acknowledgments
The authors acknowledge additional ProVent investigators, Joyce Lanier, RRT, Bob Schwartz, PhD, and Mark
Unroe, MD, for their assistance with data acquisition and data management.
This work was supported by the National Institutes of Health (R21HL094975).
REFERENCES
1. Nelson JE, Cox CE, Hope AA, et al. Chronic critical illness. Am J Respir Crit Care Med. 2010;
182:446–454. [PubMed: 20448093]
2. Cox CE, Carson SS, Holmes GM, et al. Increase in tracheostomy for prolonged mechanical
ventilation in North Carolina, 1993–2002. Crit Care Med. 2004; 32:2219–2226. [PubMed:
15640633]
3. Zilberberg MD, de Wit M, Prirone JR, et al. Growth in adult prolonged acute mechanical
ventilation: Implications for healthcare delivery. Crit Care Med. 2008; 36:1451–1455. [PubMed:
18434911]
4. Carson SS, Bach PB. The epidemiology and costs of chronic critical illness. Crit Care Clin. 2002;
18:461–476. [PubMed: 12140908]
5. Carson SS, Garrett J, Hanson LC, et al. A prognostic model for one-year mortality in patients
requiring prolonged mechanical ventilation. Crit Care Med. 2008; 36:2061–2069. [PubMed:
18552692]
6. Combes A, Costa MA, Trouillet JL, et al. Morbidity, mortality, and quality-of-life outcomes of
patients requiring >or =14 days of mechanical ventilation. Crit Care Med. 2003; 31:1373–1381.
[PubMed: 12771605]
7. Cox CE, Carson SS, Lindquist JH, et al. Differences in one-year health outcomes and resource
utilization by definition of prolonged mechanical ventilation: A prospective cohort study. Crit Care.
2007; 11:R9. [PubMed: 17244364]
8. Engoren M, Arslanian-Engoren C, Fenn-Buderer N. Hospital and long-term outcome after
tracheostomy for respiratory failure. Chest. 2004; 125:220–227. [PubMed: 14718444]
9. Unroe M, Kahn JM, Carson SS, et al. One-year trajectories of care and resource utilization for
recipients of prolonged mechanical ventilation: A cohort study. Ann Intern Med. 2010; 153:167–
175. [PubMed: 20679561]
10. Carson SS, Bach PB, Brzozowski L, et al. Outcomes after long-term acute care. An analysis of 133
mechanically ventilated patients. Am J Respir Crit Care Med. 1999; 159:1568–1573. [PubMed:
10228128]
11. Nelson JE, Mercado AF, Camhi SL, et al. Communication about chronic critical illness. Arch
Intern Med. 2007; 167:2509–2515. [PubMed: 18071175]
Carson et al. Page 7













12. Cox CE, Martinu T, Sathy SJ, et al. Expectations and outcomes of prolonged mechanical
ventilation. Crit Care Med. 2009; 37:2888–2894. [PubMed: 19770733]
13. Fried TR, Bradley EH, Towle VR, et al. Understanding the treatment preferences of se-riously ill
patients. N Engl J Med. 2002; 346:1061–1066. [PubMed: 11932474]
14. Heyland DK, Dodek P, Rocker G, et al. What matters most in end-of-life care: Perceptions of
seriously ill patients and their family members. CMAJ. 2006; 174:627–633. [PubMed: 16505458]
15. Lloyd CB, Nietert PJ, Silvestri GA. Intensive care decision making in the seriously ill and elderly.
Crit Care Med. 2004; 32:649–654. [PubMed: 15090942]
16. Cox CE, Carson SS, Govert JA, et al. An economic evaluation of prolonged mechanical
ventilation. Crit Care Med. 2007; 35:1918–1927. [PubMed: 17581479]
17. Christakis, NA. Death Foretold: Prophecy and Prognosis in Medical Care. University of Chicago
Press; Chicago, IL: 1999.
18. Christakis NA, Iwashyna TJ. Attitude and self-reported practice regarding prognostication in a
national sample of internists. Arch Intern Med. 1998; 158:2389–2395. [PubMed: 9827791]
19. Evans LR, Boyd EA, Malvar G, et al. Surrogate decision-makers’ perspectives on discussing
prognosis in the face of uncertainty. Am J Respir Crit Care Med. 2009; 179:48–53. [PubMed:
18931332]
20. Meadow W, Pohlman A, Frain L, et al. Power and limitations of daily prognostications of death in
the medical intensive care unit. Crit Care Med. 2011; 39:474–479. [PubMed: 21150582]
21. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in
longitudinal studies: Development and validation. J Chron Dis. 1987; 40:373–383. [PubMed:
3558716]
22. Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system. Risk prediction of
hospital mortality for critically ill hospitalized adults. Chest. 1991; 100:1619–1636. [PubMed:
1959406]
23. Polderman KH, Jorna EM, Girbes AR. Inter-observer variability in APACHE II scoring: Effect of
strict guidelines and training. Intensive Care Med. 2001; 27:1365–1369. [PubMed: 11511950]
24. Freeman RB Jr. Model for End-stage Liver Disease (MELD) for liver allocation: A 5-year score
card. Hepatology. 2008; 47:1052–1057. [PubMed: 18161047]
25. Kamath PS, Kim WR. The Model for End-stage Liver Disease (MELD). Hepatology. 2007;
45:797–805. [PubMed: 17326206]
26. Carson SS, Bach PB. Predicting mortality in patients suffering from prolonged critical illness: An
assessment of four severity-of-illness measures. Chest. 2001; 120:928–933. [PubMed: 11555531]
27. Nasraway SA, Button GJ, Rand WM, et al. Survivors of catastrophic illness: Outcome after direct
transfer from intensive care to extended care facilities. Crit Care Med. 2000; 28:19–25. [PubMed:
10667494]
28. Kahn JM, Benson NM, Appleby D, et al. Long-term acute care hospital utilization after critical
illness. JAMA. 303:2253–2259. [PubMed: 20530778]
29. Kane RL. Finding the right level of posthospital care. ‘We didn’t realize there was any other option
for him.’ JAMA. 2011; 305:284–293.
30. Christakis NA, Sachs GA. The role of prognosis in clinical decision making. J Gen Intern Med.
1996; 11:422–425. [PubMed: 8842935]
31. White DB, Braddock CH, Bereknyei S, et al. Toward shared decision making at the end of life in
intensive care units. Arch Intern Med. 2007; 167:461–467. [PubMed: 17353493]
32. Lynn J, Teno JM, Harrell FE Jr. Accurate prognostications of death. Opportunities and challenges
for clinicians. West J Med. 1995; 163:250–257. [PubMed: 7571588]
33. Consensus statement of the Society of Critical Care Medicine’s Ethics Committee regarding futile
and other possibly inadvisable treatments. Crit Care Med. 1997; 25:887–891. [PubMed: 9187612]
34. A controlled trial to improve care for seriously ill hospitalized patients. The Study to Understand
Prognoses for Outcomes and Risks of Treatments (SUPPORT). The SUPPORT Principal
Investigators. JAMA. 1995; 274:1541–1548.
35. Daly BJ, Douglas SL, O’Toole E, et al. Effectiveness trial of an intensive communication structure
for families of long-stay ICU patients. Chest. 2010; 138:1340–1348. [PubMed: 20576734]
Carson et al. Page 8













36. Lilly CM, De Meo DL, Sonna LA, et al. An intensive communication intervention for the critically
ill. Am J Med. 2000; 109:469–475. [PubMed: 11042236]
37. Curtis JR, Nielsen EL, Treece PD, et al. Effect of a quality-improvement intervention on end-of-
life care in the intensive care unit: A randomized trial. Am J Respir Crit Care Med. 2011;
183:348–355. [PubMed: 20833820]
38. Norton SA, Hogan LA, Holloway RG, et al. Proactive palliative care in the medical intensive care
unit: Effects on length of stay for selected high-risk patients. Crit Care Med. 2007; 35:1530–1535.
[PubMed: 17452930]
39. O’Connor AM, Bennet CL, Stacey D, et al. Decision aids for people facing health treatment or
screening decisions. Cochrane Database Syst Rev. 2009; 3:CD001431. [PubMed: 19588325]
40. Rocker G, Cook D, Sjokvist P, et al. Clinician predictions of intensive care unit mortality. Crit
Care Med. 2004; 32:1149–1154. [PubMed: 15190965]
41. Cook D, Rocker G, Marshall J, et al. With-drawal of mechanical ventilation in anticipation of
death in the intensive care unit. N Engl J Med. 2003; 349:1123–1132. [PubMed: 13679526]
42. Hakim RB, Teno JM, Harrell FE Jr, et al. Factors associated with do-not-resuscitate orders:
patients’ preferences, prognoses, and physicians’ judgments. SUPPORT Investigators. Study to
Understand Prognoses and Preferences for Outcomes and Risks of Treatment. Ann Intern Med.
1996; 125:284–293. [PubMed: 8678391]
43. Nelson JE, Meier DE, Litke A, et al. The symptom burden of chronic critical illness. Crit Care
Med. 2004; 32:1527–1534. [PubMed: 15241097]
44. Martin CM, Hill AD, Burns K, et al. Characteristics and outcomes for critically ill patients with
prolonged intensive care unit stays. Crit Care Med. 2005; 33:1922–1927. [PubMed: 16148460]
45. Hemphill JC 3rd, White DB. Clinical nihilism in neuroemergencies. Emerg Med Clin North Am.
2009; 27:27–37. [PubMed: 19218017]
Carson et al. Page 9














Kaplan-Meier curve of survival for patients by ProVent score.
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Table 4





0 72 20 (10–29)
1 60 36 (24–48)
2 78 56 (45–68)
3 36 81 (67–94)
4 or 5 14 100 (77–100)
The ProVent score is calculated by summing the point values assigned according to the presence of risk variables listed in Table 3 when measured
on day 21 of mechanical ventilation.
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